Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Improved Retention, Outcomes With Same-Day HIV Testing and Treatment

By PLOS | July 27, 2017

Initiating antiretroviral therapy (ART) on the same day as HIV testing is feasible and leads to improved retention and health outcomes, according to a trial published in PLOS Medicine.

Standard care for patients who test positive for HIV in most settings involves multiple visits for counseling and laboratory procedures to prepare patients for ART initiation and determine eligibility, but this process typically takes weeks and can be a barrier to starting treatment. To determine if accelerating this process can improve retention and health outcomes, Serena Koenig of Brigham and Women’s Hospital, USA, Jean William Pape of Weill Medical College of Cornell University, USA, and their colleagues conducted a randomized trial of same-day ART initiation at the GHESKIO Centers in Port-au-Prince, Haiti. Adults testing positive for HIV with early stage disease were randomized to either standard care (3 weekly visits with a social worker and physician before starting ART), or same-day ART (starting treatment on the day of HIV diagnosis). They found that 12 months after HIV testing, retention in care was improved (80% of participants in the same-day ART group versus 72% of the standard care group), as was evidence that ART was working (53% versus 44% with viral load <50 copies/ml; 61% versus 52% with viral load <1,000 copies/ml).

The authors note that further study is necessary to determine if this strategy will be effective in settings other than a large urban clinic, and that despite the improvements shown here, both retention and suppression rates will need to improve further to hit UNAIDS 90-90-90 targets and maximize long-term outcomes. Nevertheless, they note that “These results are important given recent WHO 2016 guidelines stating the lack of evidence in support of same-day ART initiation.”

In a linked perspective, Elvin Geng of the University of California, San Francisco, USA, notes that this study is “a critical step toward addressing the knowledge gap about how fast to start ART”, and discusses the need to develop approaches to support same-day ART start and improve retention and adherence on a larger scale.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE